Monday, October 02, 2017 10:15 PM ET
CymaBay Therapeutics (CBAY) sees a Significant Insider Sale Slowing Buy Trend Over Last 90 Days
A filing with the SEC today revealed a substantial insider sale of CymaBay Therapeutics shares as — Kurt von Emster, Director — sold 211,124 shares in the company having a market value of approximately $1,707,380. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the acquisition of 20,000 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 191,124 shares and have averaged 57,781 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at CymaBay Therapeutics is higher than its 264-company peer group average. The Bio Therapeutic Drugs peer group saw 313 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by CymaBay Therapeutics insiders is lower than its peers. Within the peer group there were 8,809,358 shares purchased and 20,407,778 shares sold with company insiders selling 37,056 shares on average over this time period.
Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data used in composing and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.